Resveratrol in the management of human cancer: how strong is the clinical evidence?
Resveratrol in the management of human cancer: how strong is the clinical evidence?
复制标题
DOI：
10.1111/nyas.12205
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Brown, Karen
中科院分区：
文献类型：
--
作者：
Gescher, Andreas;Steward, William P.;Brown, Karen
在临床前系统中白藜芦醇参与的众多生化机制中，其抗癌作用是最具说服力和吸引力的。正如本文所述，人们对开发白藜芦醇用于癌症预防和治疗非常感兴趣。白藜芦醇在人体内的血浆药代动力学现已相当明确，研究表明每日重复剂量达1g是安全且耐受性良好的，尽管在较高的摄入量下观察到胃肠道毒性。然而，需要注意特定患者群体的潜在疾病，并且剂量大于1克时可能存在药物相互作用。人们对白藜芦醇在人体中的药效学作用知之甚少，但观察到它可以调节志愿者血浆中胰岛素样生长因子系统的组成部分，这是令人鼓舞的。虽然近年来有助于确定白藜芦醇在癌症治疗中是否有用的知识基础大大增加，但重要的问题仍然存在。
Among the plethora of biochemical mechanisms engaged by resveratrol in preclinical systems, its anticarcinogenic effects represent some of the most convincing and intriguing. As outlined in this review, there is considerable interest in developing resveratrol for cancer prevention and treatment. The plasma pharmacokinetics of resveratrol in humans are now reasonably well defined, and studies have shown that repeated daily doses up to 1 g are safe and well tolerated, although gastrointestinal toxicity is observed at higher intakes. However, care is needed regarding underlying conditions in specific patient groups, and there is potential for drug interactions at doses greater than 1 gram. Little is known regarding the pharmacodynamic effects of resveratrol in humans, but the observation that it modulates components of the insulin-like growth factor system in the plasma of volunteers is encouraging. While the knowledge base that helps determine whether resveratrol may be useful in cancer management has increased substantially in recent years, important questions remain.